Teneligliptin 20 mg + Metformin 1000 mg PCD Pharma

Brand Name

TNBEST-M Forte Tablet (Bilayered)

Composition

Teneligliptin 20mg & Metformin 1000mg (Sustained Release)

Therapeutic Use

ANTIDIABETICS

Size

10 x 10

Verified Exporter

Verified Seller

Trusted Pharma

Description

TNBEST-M Forte Tablet (Bilayered) contains Teneligliptin 20 mg and Metformin 1000 mg sustained-release (SR), a combination of oral antidiabetic agents used to help manage blood glucose levels in adults with type 2 diabetes mellitus when prescribed by a qualified healthcare professional. Teneligliptin belongs to the dipeptidyl peptidase-4 (DPP-4) inhibitor class, while metformin is a biguanide that primarily reduces glucose production in the liver and improves insulin sensitivity.

The two active ingredients work through complementary mechanisms to support glycaemic control. This combination may be considered when a clinician determines that both medicines are appropriate as part of an individualised diabetes management plan that includes dietary measures, physical activity and regular blood glucose monitoring.

CardianCare focuses on cardiac and diabetic healthcare products for healthcare professionals and pharmaceutical business partners. Businesses searching for a Teneligliptin 20 mg + Metformin 1000 mg SR Tablets manufacturer India can enquire about current product availability, approved specifications, manufacturing details and relevant quality documentation.

For procurement teams evaluating a Teneligliptin 20 mg + Metformin 1000 mg SR Tablets manufacturer and supplier India, important considerations include composition accuracy, sustained-release characteristics, bilayered Tablet specifications, product authorisation, batch traceability, packaging and commercial supply terms.

2. Key Ingredient

Composition:

Teneligliptin 20 mg + Metformin 1000 mg SR

Teneligliptin 20 mg: Teneligliptin is an oral antidiabetic agent classified as a DPP-4 inhibitor. It slows the breakdown of incretin hormones, including GLP-1 and GIP, helping support glucose-dependent insulin secretion and regulate glucagon release when blood glucose levels are elevated.

Metformin 1000 mg SR: Metformin is a biguanide antidiabetic medicine that primarily reduces glucose production in the liver and improves the body’s response to insulin. The sustained-release formulation is designed to release the medicine over an extended period according to its approved formulation specifications.

Together, these ingredients provide complementary approaches to blood glucose regulation. The suitability of the combination depends on the patient’s medical history, kidney function, existing medicines and the approved prescribing information.

Businesses researching a Teneligliptin 20 mg + Metformin 1000 mg SR pharmaceutical company India should review the active ingredients, release characteristics, product authorisation, manufacturing source and applicable quality documentation.

Companies seeking a Teneligliptin 20 mg + Metformin 1000 mg SR medicine manufacturer India should verify the authorised manufacturing facility, approved product specifications, batch-specific records and applicable regulatory requirements before procurement.

3. Key Benefits

Complementary glucose control: Combines two antidiabetic agents with different mechanisms to help manage blood glucose in eligible adults with type 2 diabetes.

Incretin hormone support: Teneligliptin helps prolong incretin activity involved in glucose-dependent insulin secretion and glucagon regulation.

Hepatic glucose regulation: Metformin helps reduce glucose production in the liver and improves insulin sensitivity.

Sustained-release formulation: The metformin SR component is designed for extended drug release according to the approved product specifications.

Bilayered dosage form: Brings the specified active ingredients together in a bilayered Tablet, subject to the approved formulation design.

Individualised diabetes management: May be incorporated into a treatment plan that includes medical supervision, dietary planning, physical activity and blood glucose monitoring.

Clinical outcomes vary between patients. This medicine does not replace lifestyle measures, regular monitoring or professional medical follow-up.

Pharmaceutical buyers searching for a Teneligliptin 20 mg + Metformin 1000 mg SR supplier India should verify product authenticity, approved composition, availability, packaging, shelf life and continuity of supply.

A Teneligliptin 20 mg + Metformin 1000 mg SR Tablet wholesaler and distributor India enquiry may include stock availability, minimum order quantities, distribution eligibility, delivery coverage and applicable commercial terms.

Businesses seeking a Teneligliptin 20 mg + Metformin 1000 mg SR bulk supplier India should request a formal quotation and confirm batch traceability, storage requirements, packaging specifications and quality documentation.

A Teneligliptin 20 mg + Metformin 1000 mg SR pharmaceutical distributor India should verify relevant licensing requirements, product availability and approved promotional information before starting commercial activities.

4. How Does It Work?

The two active ingredients support blood glucose regulation through different pathways.

Teneligliptin inhibits the DPP-4 enzyme, which breaks down incretin hormones such as GLP-1 and GIP. Prolonging their activity helps support glucose-dependent insulin secretion and regulate glucagon release when blood glucose levels are elevated.

Metformin primarily reduces glucose production in the liver and improves insulin sensitivity, helping the body regulate blood glucose more effectively.

Together, these actions can provide complementary glucose-lowering effects in eligible adults with type 2 diabetes. The risk of hypoglycaemia may increase when this combination is used with insulin or sulfonylureas. Metformin also requires particular attention to kidney function and the risk of lactic acidosis in susceptible patients.

5. Directions for Use

Dosage: Take only as prescribed by a qualified doctor. The appropriate regimen depends on the patient’s previous treatment, blood glucose control, kidney function and the approved product label.

Administration: Follow the approved product instructions for this bilayered sustained-release Tablet. Do not crush, chew or split it unless the approved product information specifically permits this.

With food: Metformin SR is commonly taken with food to improve gastrointestinal tolerability. Follow the exact product instructions and the prescriber’s advice.

Regular timing: Follow the prescribed schedule consistently. Do not change the dose or timing without medical advice.

Kidney function: Kidney function should be assessed before treatment and monitored as clinically appropriate.

Other medicines: Inform the doctor about insulin, sulfonylureas and all other prescription medicines, over-the-counter products and supplements.

Missed dose: Follow the patient leaflet or ask a pharmacist or doctor for advice. Do not take a double dose to make up for a missed dose.

Monitoring: Continue recommended blood glucose monitoring, dietary measures, physical activity and follow-up appointments.

Do not start, stop or change treatment independently. The prescriber should determine whether this combination is suitable for the individual patient.

6. Possible Side Effects

Possible side effects may include:

Nausea

Diarrhoea

Abdominal discomfort

Bloating or gas

Reduced appetite

Vomiting or indigestion

Metformin-related gastrointestinal symptoms may be more noticeable when treatment begins or the dose changes.

Important adverse reactions and warning signs include:

Hypoglycaemia: The risk may increase when the combination is used with insulin or sulfonylureas. Symptoms can include sweating, shakiness, dizziness, confusion or unusual weakness.

Lactic acidosis: A rare but potentially life-threatening complication associated with metformin. Severe weakness, muscle pain, breathing difficulty, unusual sleepiness or abdominal symptoms require urgent medical attention.

Vitamin B12 deficiency: Long-term metformin use may reduce vitamin B12 levels in some patients. Monitoring may be appropriate when clinically indicated.

Pancreatitis: Severe, persistent abdominal pain, particularly if it radiates to the back, requires urgent medical assessment.

Allergic reactions: Serious swelling, breathing difficulty or a severe rash requires emergency care.

Dehydration or acute illness: Significant vomiting, diarrhoea or reduced fluid intake can affect kidney function and increase treatment-related risks.

This list is not exhaustive. Consult a healthcare professional about persistent or concerning symptoms and refer to the approved product information for the full safety profile.

7. Safety Information

Medical supervision: Use only under the guidance of a qualified healthcare professional.

Allergies: Do not use if there is a known serious allergy to either active ingredient or any component of the formulation.

Kidney health: Metformin may be unsuitable in severe renal impairment. Kidney function must be assessed before treatment and monitored as advised.

Liver health: Inform the prescriber about liver disease because it may increase the risk of metformin-associated lactic acidosis.

Acute illness and dehydration: Severe infection, persistent vomiting or diarrhoea, dehydration or reduced food and fluid intake may require treatment review by a clinician.

Surgery and contrast procedures: Tell the healthcare team about metformin use before surgery or imaging involving iodinated contrast. The clinician will advise whether temporary interruption is necessary.

Alcohol: Avoid excessive alcohol intake and discuss alcohol use with the doctor because it can increase the risk of metformin-associated lactic acidosis.

Pancreatic symptoms: Seek urgent assessment if severe, persistent abdominal pain suggests pancreatitis.

Pregnancy and breastfeeding: Consult a doctor before use during pregnancy, when planning pregnancy or while breastfeeding. The clinician should review the most appropriate diabetes treatment.

Drug interactions: Tell the doctor about all medicines, especially insulin, sulfonylureas and medicines that may affect kidney function or blood glucose.

Storage: Store in the original packaging according to the approved label, protected from excessive heat and moisture and out of reach of children.

This information is educational and does not replace approved prescribing information or individual medical advice.

8. B2B Pharmaceutical Business Enquiries

CardianCare focuses on cardiac and diabetic healthcare products for healthcare professionals and pharmaceutical business partners. Pharmaceutical distributors, wholesalers, pharmacists and eligible trade partners should confirm current product availability, approved specifications and commercial arrangements directly with the company.

Businesses researching a Teneligliptin 20 mg + Metformin 1000 mg SR PCD pharma franchise India opportunity can enquire about current product listings, partner eligibility, territory terms and applicable business requirements.

For a Teneligliptin 20 mg + Metformin 1000 mg SR Tablets PCD pharma franchise enquiry, prospective partners can request information about product availability, minimum order requirements, distribution eligibility and any promotional support that may be available.

Companies exploring a Teneligliptin 20 mg + Metformin 1000 mg SR Tablet PCD franchise should confirm whether the formulation is included in a current programme before making investment or promotional commitments.

Businesses evaluating Teneligliptin 20 mg + Metformin 1000 mg SR third party manufacturing India services should first confirm whether the proposed company offers such arrangements. Relevant checks include manufacturing permissions, product authorisation, applicable GMP compliance, minimum batch quantities and quality documentation.

A Teneligliptin 20 mg + Metformin 1000 mg SR Tablet third party manufacturer India enquiry should cover the authorised manufacturing facility, bilayered formulation capabilities, sustained-release specifications, quality systems, batch release procedures and packaging requirements.

Companies researching Teneligliptin 20 mg + Metformin 1000 mg SR contract manufacturing India should confirm service availability directly with the proposed manufacturing partner. Relevant discussions may include formulation specifications, technical documentation, quality agreements, regulatory responsibilities, manufacturing authorisation and commercial feasibility.

Contact CardianCare through its official website to enquire about current product availability and eligible pharmaceutical business opportunities. Distribution, PCD franchise, third-party manufacturing and contract manufacturing services must be confirmed directly with the company before being represented as available.

For more information about TNBEST-M Forte Tablet (Bilayered) – Teneligliptin 20 mg + Metformin 1000 mg SR, click here

Frequently Asked Questions

This combination is used to help manage blood glucose in adults with type 2 diabetes mellitus when prescribed appropriately. It should be used alongside recommended dietary measures, physical activity and medical monitoring.

The supplied composition is Teneligliptin 20 mg and Metformin 1000 mg sustained-release (SR). Teneligliptin is a DPP-4 inhibitor, while metformin is a biguanide antidiabetic agent.

Teneligliptin prolongs incretin hormone activity to support glucose-dependent insulin secretion and glucagon regulation. Metformin primarily reduces glucose production in the liver and improves insulin sensitivity.

A bilayered Tablet contains two distinct layers in a single dosage form. Its exact release design and formulation characteristics must be confirmed against the approved product specifications.

Take it exactly as prescribed and follow the approved product label. Do not crush, chew or split the sustained-release bilayered Tablet unless the product information explicitly permits this.

Possible effects include nausea, diarrhoea, abdominal discomfort, bloating and reduced appetite. Important warning signs include symptoms of lactic acidosis, severe abdominal pain, serious allergic reactions or significant hypoglycaemia.

People with kidney or liver disease, dehydration, a history of pancreatitis, significant allergies, pregnancy or breastfeeding considerations, or other major medical conditions should discuss suitability with their healthcare professional.

Additional antidiabetic medicines may sometimes be prescribed as part of an individual treatment plan. Combining therapies can change the risk of hypoglycaemia and other adverse effects, so the regimen must be reviewed by a clinician.

Verify the exact composition, metformin sustained-release characteristics, bilayered dosage form, product authorisation, manufacturing source, quality documentation, batch traceability, shelf life, packaging and commercial terms.

Eligible pharmaceutical businesses can contact CardianCare through its official website to ask about current product availability and applicable distribution or franchise arrangements. Confirm all services, eligibility criteria and commercial terms directly with the company."

Reviews

There are no reviews yet.

Be the first to review “Teneligliptin 20 mg + Metformin 1000 mg PCD Pharma”

Your email address will not be published. Required fields are marked *

Enquiry Now
close slider

    Drop us a Line